22:22 , Mar 18, 2019 |  BC Extra  |  Company News

Astellas adds more drug delivery tech via NapaJen deal

Astellas has completed a second deal for a drug delivery technology, this time with NapaJen, that stands to add a new modality to its pipeline. Astellas Pharma Inc. (Tokyo:4503) will use oligonucleotide delivery technology from...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed March 1 to raise up to $100 million in an IPO on NASDAQ. Precision plans to start...
00:53 , Mar 2, 2019 |  BC Extra  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ. Precision plans to start this...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
23:41 , Aug 3, 2018 |  BioCentury  |  Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
23:11 , Jun 7, 2018 |  BC Week In Review  |  Clinical News

Exact HCC assay significantly better than SOC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test. The...
00:24 , Jun 6, 2018 |  BioCentury  |  Product Development

Second (Ex)act

Armed with Phase II data for its second DNA methylation test, Exact Sciences Corp. expects a repeat performance of the rapid launch trajectory its Cologuard colorectal cancer screening assay has enjoyed. Cologuard beat expectations for...